Contact this trialFirst, we need to learn more about you.
Virus Therapy
LAIV for Flu
Recruiting1 awardPhase < 1
Birmingham, Alabama
This trial is testing the hypothesis that the T-bet expressing fraction of flu-specific B cells after receiving the live attenuated influenza vaccine (LAIV) serves as an early biomarker of long-lived antibody responses after vaccination.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.